Given that AD disproportionately affects women, and drugs targeting the GH/IGF-1R pathway already exist, a better understanding of IGF-1 signaling on brain aging and AD, and potential sex-specific effects are needed, as it could hold important therapeutic implications. Here, IGF1 is linked to Alzheimer disease.